All In Biotech

Drug Trial Radar · NCT06062875

Effects of TNF Blockade on Human BPH/LUTS

Last checked: Nov 20, 2026Latest source record: Nov 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Jan 24, 2024

Primary completion

Apr 1, 2028

Study completion Jun 1, 2028

Sponsor

Lead sponsor
Endeavor HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted
Oct 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Male only, from 45 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Specific Aim 1. To evaluate the efficacy of TNF antagonist action in BPH/LUTS Specific Aim 2. Define the consequences of TNF antagonist therapy on prostate tissue Specific Aim 3. Identify genetic predictors to stratify patients with differential response to TNF-antagonist therapy.

Conditions

  • Benign Prostatic Hyperplasia (BPH)

Interventions

  • AdalimumabDrug

    Adalimumab will be delivered subcutaneously (under the skin) at a dose of 40mg every 2 weeks for a total of 6 doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. International Prostate Symptom ScoreTime frame: The past 30 days
  2. Safety as measured by Clavien-Dindo grading systemTime frame: Through study completion (Week 24)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • NorthShore University HealthSystem

    Glenview, Illinois · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.